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A  highly  sensitive  and rapid liquid  chromatography  tandem  mass  spectrometry  (LC–MS/MS)  method  has
been  developed  to measure  the  levels  of  the  antitubercular  drug  rifampicin  (RIF)  in human  plasma  and
cerebrospinal  ﬂuid  (CSF).  The  analyte  and  internal  standard  (IS)  were  isolated  from  plasma  and  CSF  by a
simple  organic  solvent  based  precipitation  of  proteins  followed  by  centrifugation.  Detection  was carried
out  by electrospray  positive  ionization  mass  spectrometry  in  the multiple-reaction  monitoring  (MRM)






of  <7%  and  <8%,  respectively.  The  validated  method  was  applied  to  the  study  of  RIF  pharmacokinetics  in
human  CSF  and  plasma  over  25  h  period  after  a 10 mg/kg  oral  dose.
© 2012 Elsevier B.V. Open access under CC BY license.uantitative  assay
. Introduction
Tuberculosis (TB) is one of the most important human bacterial
iseases caused by mycobacterium tuberculosis (MTB) commonly
ffecting the lungs [1]. It is an aggressive disease with one third of
he World’s population reportedly being infected with MTB  [1,2].
t is more common in developing countries, with more than half
f the reported cases occurring in Asia [1]. Rifamycins are a group
f complex, macrocyclic antibiotics produced by Amycolatopsis
editerranei that are one of the most important ﬁrst line anti-TB
rugs [3]. Among them RIF has been used for the treatment of TB,
eprosy [4,5], some types of osteomyelitis and endocarditis [6].
he drug is most regularly deployed in the cocktail of drugs used
s ﬁrst-line treatment for TB. RIF inhibits DNA-dependent RNA
olymerase in bacterial cells. Although the drug has been in use for
any decades there are still questions about the appropriateness of
osage regimes in speciﬁc patient groups such as those co-infected
ith HIV and young children. In order to address these questionshere is a need for a suitably selective and sensitive analytical
ethod that is capable of measuring the drug in biological ﬂuids.
everal analytical methods are already available for the deter-
Abbreviations: CSF, cerebrospinal ﬂuid; MTB, mycobacterium tuberculosis; RPT,
ifapentine; RIF, rifampicin; TB, tuberculosis.
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forms, including methods based on HPTLC [7], HPLC [8–16], HPLC
following SPE [17] or SBSE [18], UPLC [19], LC–MS/MS [20–23] and
MALDI–TOF [24]. In all cases there are some drawbacks associated
with existing methods making them unsuitable for satisfac-
tory quantitative analysis in studies that have been designed and
implemented as part of an integrated TB clinical pharmacology pro-
gramme  in the Liverpool School of Tropical Medicine. In some cases
there is no inclusion of an IS which compromises the robustness of
the method [8,15,17], some assays need relatively large volumes
of sample and/or lacked sensitivity which limits their usefulness in
pediatric studies where sample volumes are severely constrained
[12–14] and other assays involve complex or very long extraction
procedures thereby compromising throughput [10,11,13,16]. The
aim of the work presented here was to develop a rapid and sensitive
LC–MS/MS method for the quantiﬁcation of RIF in human plasma
and CSF samples. We have established an exacting, sensitive and
reproducible analytical method requiring only a small sample
volume and involving quick sample processing as key beneﬁts
of this assay for the quantitative analysis of RIF. The developed
method was  validated according to the FDA guidelines [25].
2.  Materials and methods2.1.  Solvents and chemicals
RIF  (C47H64N4O12; MW 822.94) and rifapentine (RPT; C15H24O5;
MW 877.03) were purchased from Sigma–Aldrich (Poole, Dorset,











































































cFig. 1. Chemical st
K). The structures of RIF and RPT are given in Fig. 1. Methanol,
ater and acetonitrile were all HPLC grade from Fisher Scientiﬁc UK
Loughborough, Leicestershire, UK). All other solvents were of HPLC
rade and unless otherwise speciﬁed all other reagents were pur-
hased from Sigma–Aldrich. Drug free human plasma was obtained
rom the National Blood Service. Artiﬁcial CSF was obtained from
arvard Apparatus (Holliston, MA,  USA).
.2. Equipment
The HPLC system consisted of a variable loop Accela autosam-
ler (200 vial capacity set at a temperature of 4 ◦C) and an Accela
C pump (Thermo Electron Corporation, Hemel Hempstead, UK). A
everse-phase Hypersil–Hypurity C18 column (150 mm × 2.1 mm,
.d., 5 m;  Thermo Electron Corporation, Hemel Hempstead, UK)
et at room temperature was used to elute RIF and RPT. The
PLC system was interfaced with a triple-quadrupole TSQ Quan-
um Access mass spectrometer (Thermo Electron Corporation,
emel Hempstead, UK) ﬁtted with an electrospray ionization (ESI)
ource. One E2M30 rotary vacuum pump (Edwards High Vac-
um International, West Sussex, UK), a nitrogen generator (Nitro
enerator, Products of Technology Ltd., Killearn, UK) and 99%
ure argon gas (10 L BIP Gas, Air Products, Crewe, UK) were
sed.
.3. Standard solutions
RIF  and RPT, used as the IS, were weighed from solid to an
ppropriate amount. Solids were then dissolved in methanol to
ive 1 mg/mL  primary stock solutions. Appropriate dilutions were
hen made in methanol to produce working stock solutions of 320,
60, 80, 40, 20, 10, 2.5, and 1.25 g/mL. Another set of working
tock solutions was made in methanol (from re-weighed primary
tock) at 240, 30 and 3.75 g/mL for preparation of QC samples
ccordingly. Aliquots of each working solution were diluted 50
old with drug-free plasma or CSF to obtain eight calibration stan-
ards (CS) and three levels of quality control (QC) samples, namely
igh (HQC), medium (MQC) and low QC (LQC). CS were made
p fresh with each new analytical run whereas QC samples were
rawn form a stock of QC samples stored in a −80 ◦C freezer at the
nset of the RIF analytical programme. A working IS stock solu-
ion containing 250 ng/mL of RPT was accurately made up (total
olume: 400 mL;  stored at −20 ◦C, under dark conditions) by dilut-
ng 1 mg/mL  stock solution with 50% ACN and 50% methanol. Both
IF and RPT are light sensitive. In order to minimize/eliminate
ight dependent decomposition all working solutions were stored
n the dark and all sample extraction and preparation procedures
ere performed in a darkened fume cupboard and biological safety
abinet.res of compounds.
2.4. Sample preparation
Frozen  plasma and CSF samples from study subjects & QC sam-
ples were thawed as needed. The same procedure was followed for
all samples. 100 l of each of the CS, QC and test samples was  trans-
ferred into clean 1.5 mL  microfuge tubes. 300 l of IS (250 ng/mL
RPT in 50/50 ACN/methanol) was added and the tubes were
vortexed vigorously to allow for maximal protein precipitation.
Samples were centrifuged (25 min, 16,200 × g) and supernatants
(200 l) transferred to clean glass autosampler vials for LC–MS/MS
analysis.
2.5. Chromatographic and mass spectrometric conditions
Chromatographic separation was achieved using a rapid step-
wise mobile phase gradient operating at a ﬂow rate of 350 l/min
over a total run time of 6 min. The mobile phase consisted of a
combination of ACN containing formic acid (0.05%, v/v) and 15 mM
ammonium formate buffer (pH 5). A sample aliquot of 50 l was
injected onto the column, and eluted with a gradient of 35–90%
ACN from 0 to 4 min, increasing to 95% ACN from 4 to 5 min, and
ﬁnally reverting to 35% ACN from 5 to 6 min.
Quantitation was achieved by MS–MS  detection in positive ion-
ization mode for both RIF and IS. The MS  operating conditions were
optimized as following: the spray voltage was  4500 V with a tube
lens voltage of 124 V and skimmer offset of 0 V. The capillary tem-
perature was set to 275 ◦C. Nitrogen was used as the sheath gas
(40 psi) and auxiliary gas (25 psi). Argon was used as the collision
gas at a pressure of 1.5 mTorr (1 Torr = 133.3 Pa). The optimized
collision energies for RIF and IS were 10 and 30 eV, respectively.
Detection of the ions was performed in the MRM  mode using the
transitions of m/z 823.4 → 791.4 for RIF and m/z 877.4 → 150.8 for
RPT (IS), respectively, with a scan time of 0.1 s per transition. TSQ
Tune Software (Thermo Electron Corporation, Hemel Hepstead, UK)
was used for the automatic optimization of tuning parameters. Data
acquisition was  performed using Xcalibur 1.3 software (Thermo
Electron Corporation, Hemel Hepstead, UK). Peak integration and
calibrations were performed using LC QuanTM software (Version
2.5.6, Thermo Electron Corporation, Hemel Hempstead, UK).
2.6.  Validation of quantitative LC–MS/MS method
The quantitative LC–MS/MS method was  validated to determine
selectivity, calibration range, accuracy, precision, limit of detection
(LOD), limit of quantitation, % recovery, matrix effects, freeze–thaw,
autosampler and heat inactivation stability. The initial assay was
fully validated for RIF analysis in human plasma according to FDA
guidelines. Thereafter a partial validation was carried out for RIF
analysis in CSF samples as the only alteration was  the change in
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.6.1. Selectivity
The  selectivity of the method was evaluated by analysing six
ndependent drug-free plasma samples with reference to potential
nterferences from isobaric endogenous and environmental con-
tituents.
.6.2. Calibration curve
Calibration  curves were generated to conﬁrm the relationship
etween the peak area ratios and the concentration of RIF in
he standard samples. Fresh CS were extracted and assayed as
escribed above on three different days and in duplicate. Calibra-
ion curves for RIF were represented by the plots of the peak-area
atio (RIF/RPT) versus the nominal concentration of the RIF in CS.
he line of best ﬁt was generated using 1/concentration2 weighted
uadratic regression as the mathematical model of best ﬁt. RIF
oncentrations in QC samples, recovery samples, stability samples
nd experimental CSF/plasma pharmacokinetic samples were cal-
ulated from the resulting area ratio and the regression equation
f the calibration curve.
.6.3.  Accuracy and precision
Intra-day accuracy and precision were evaluated by analysis of
Cs at four levels (LLOQ, LQC, MQC  and HQC; n = 6 at each level)
n the same day. Inter-day precision and the accuracy were deter-
ined by analysing four QC levels on 3 separate days (n = 6 at each
evel) along with three separate standard curves done in duplicates.
he accuracy of an analytical method describes how close the mean
est results obtained by the method are to the nominal concen-
ration of the analyte. Accuracy was calculated by the following
quation, expressed as a percentage:
ccuracy (%) = mean observed concentration
nominal concentration
× 100
The precision was expressed by coefﬁcient of variation (CV). The
V % indicates the variability around the mean in relation to the size
f the mean, and is deﬁned as:
V (%) = standard deviation
mean observed concentration
× 100
.6.4.  Limit of detection and limit of quantiﬁcation
The lower limit of quantiﬁcation (LLOQ) was determined based
n the criterion that the analyte response at LLOQ is ﬁve times
aseline noise and it is within the acceptable limit of accuracy and
recision. Higher limit of quantiﬁcation (HLOQ) was  assigned to
he highest point in the standard curve. Intra-day and inter-day
ccuracy and precision for HLOQ and LLOQ samples were evalu-
ted in the same manner as the QC samples (Section 2.6.3). The
OD was determined as the lowest concentration which gives a
ignal-to-noise ratio of three for the analytes.
.6.5. Carryover test
Carry  over tests were performed by injection of blank plasma
ample directly after the highest point in calibration curve.
.6.6.  Stability
Autosampler, freeze–thaw and plasma heat-inactivation sta-
ility of RIF was determined at low, medium and high QC
oncentrations. To determine the impact of plasma heat inactiva-
ion or freeze–thaw cycles on RIF concentration, samples were heat
nactivated for 40 min  at 58 ◦C or underwent 3 freeze (−80 ◦C) thaw
room temperature) cycles. Following sample treatment/storage
onditions, the RIF concentrations were analyzed in triplicates and
ompared to the control sample that had been stored at −80 ◦C.
utosampler stability of extracted samples was  determined byd Biomedical Analysis 70 (2012) 523– 528 525
comparing RIF concentration in freshly prepared samples and sam-
ples kept in autosampler at 4 ◦C for 24 h.
2.6.7. % recovery and matrix effect
Recovery was  determined by comparing the area under the
curve (AUC) of extracted QC samples (LQC, MQC  and HQC)
with direct injection of extracted blank plasma spiked with the
same nominal concentration of RIF as in the QC samples. This
should highlight any loss in signal due to the extraction pro-
cess. IS recovery was  determined for a single concentration of
250 ng/mL.
Matrix  effects were evaluated using heat-treated and untreated
blank human plasma from six different donors using post-column
infusion experiments as described by Hanpithakpong et al. [26].
Post column infusion provides a visual assessment of the effect of
the sample matrix over an entire chromatographic run to ensure
that no interfering peaks are found in the elution windows of ana-
lytes and IS. The syringe pump of the MS  was setup containing
a mixture of 250 ng/mL RIF and RPT in methanol. This solution
was infused directly through a T-connector in to the MS  at a
constant ﬂow rate of 10 l/min, whilst the blank plasma extract
was injected via the autosampler. The chromatograms produced
were compared to an injection of mobile phase. Any ion suppres-
sion could be seen as a change in deviation in the response of
the infused analyte that was greater than the underlying system
noise.
Moreover, estimation of the matrix effects was also obtained
by comparing the peak area for samples spiked in elution solu-
tion with extracted blank matrix spiked with the same nominal
concentration of RIF.
2.7.  Data analysis
LC–MS  data acquisition and processing was  performed by LC
QuanTM software. Standard curves for quantiﬁcation of RIF were
constructed using a 1/concentration2 weighted quadratic regres-
sion of the peak area ratio versus RIF concentration. Unknown and
QC sample concentrations were back-calculated from the standard
curves.
3. Results and discussion
3.1.  Detection and chromatography
Fig.  2 shows the typical chromatograms of a blank human
plasma sample (A), a spiked plasma sample with RIF (5.0 ng/mL,
LLOQ) and IS (250.0 ng/mL) (B), a plasma sample from a patient
25 h after a 10 mg/kg oral dose of RIF (C) and a CSF sample from a
patient receiving a 10 mg/kg daily oral dose of RIF (D). The retention
times for RIF and IS were 2.1 and 2.8 min, respectively.
3.2.  Method validation
3.2.1.  Selectivity
The  method was found to have high selectivity for the
analytes, since no interfering peaks from endogenous com-
pounds were observed at the retention time for RIF or RPT
in any of the six independent blank plasma extracts evaluated
(Fig. 2A).
3.2.2. Calibration curves
Calibration  curves for RIF in human plasma and CSF were ﬁt-ted by weighted 1/concentration2 quadratic regression, with the r2
values of >0.99 for all curves generated during the validation and
pharmacokinetic plasma analysis. The calibration curve accuracy
for plasma is presented in Table 1 demonstrating that measured


























I, m/z 823.4 791.4→
II, m/z 877.4 150.8→
I, m/z 823.4 791.4→
II, m/z 877.4 150.8→
I, m/z 823.4 791.4→




























































I, m/z 823.4 791.4→
II, m/z 877.4 150.8→
Fig. 2. Representative MRM  chromatograms of RIF (I) and RPT (II, IS) in: (A) a blank
human plasma sample; (B) a blank human plasma sample spiked with RIF at the
LLOQ of 25 ng/mL; (C) patient plasma sample 25 h after an oral dose of 10 mg/kg (RIF









Aral dose of RIF (RIF concentration; 41.83 ng/mL). Sample preparation for 100 l of
B)–(D) was  performed using 300 l of 50/50 ACN/methanol (including 250 ng/mL
S), whereas IS was  not included in case of (A).
oncentration is within ±15% of the actual concentration point (20%
or the lowest point on the standard curve, the LLOQ). Results were
alculated using peak area ratios. (Calibration curve data for CSF
ot shown)
able 1
nalysis of plasma CS.
Nominal
conc. (ng/mL)
Mean conc.a (ng/mL) CV (%) Accuracy (%)
CS-1 25.00 24.48 ± 2.0 8.15 97.91
CS-2 50.00 49.42 ± 3.8 7.68 98.83
CS-3 200.00 198.65 ± 14.27 7.19 99.33
CS-4 400.00 426.72 ± 9.44 2.21 106.68
CS-5 800.00 793.48 ± 78.86 9.94 99.19
CS-6 1600.00 1550.05 ± 76.84 4.96 96.88
CS-7 3200.00  3250.46 ± 227.62 7.00 101.58
CS-8 6400.00 6377.16 ± 205.98 3.23 99.64
a Data represent the mean ± S.D of six observations.d Biomedical Analysis 70 (2012) 523– 528
3.2.3. Accuracy and precision
A detailed summary of the intra-day and inter-day precision
and accuracy data generated for the assay validation is presented
in Table 2. Inter-assay variability was expressed as the accuracy
and precision of the mean QC concentrations (LLOQ, LQC, MQC,
and HQC) of three separate assays. Intra-assay variability was
determined as the accuracy and precision of the six individual
QC concentrations within one assay. The inter- and intra-assay
accuracy and precision was <10% for all QC concentrations, which
was within the general assay acceptability criteria for QC samples
according to FDA guidelines [25].
3.2.4. Limit of detection and limit of quantiﬁcation
LOD was  deﬁned as the lowest concentration that produced a
peak distinguishable from background noise (minimum ratio of
3:1). The approximate LOD was 2.5 ng/mL. The LLOQ has been
accepted as the lowest points on the standard curve with a relative
standard deviation of less than 20% and signal to noise ratio of 5:1.
Results at lowest concentration studies (25 ng/mL) met the crite-
ria for the LLOQ (Table 2). The method was  found to be sufﬁciently
sensitive for the determination of RIF in human plasma samples
and CSF. The HLOQ has been accepted as the highest points on the
standard curve with a relative standard deviation of less than 15%
[25].
3.2.5. Carryover test
A  critical issue with the analysis of many drugs is their tendency
to get absorbed by reversed phase octadecyl-based chromato-
graphic packing materials, resulting in the memory effect. However
in this analysis no quantiﬁable carryover effect was obtained when
a series of blank (plasma) solutions were injected immediately fol-
lowing the highest calibration standard.
3.2.6. Stability studies
The  results of autosampler, freeze–thaw and heat-inactivation
stability are presented in Table 3. Determination of RIF sta-
bility following three freeze–thaw cycles showed that for all
QC samples there was  a minor change in the RIF concentra-
tion. In contrast heat-inactivation showed major impact on the
RIF concentrations measured for LQC (20.9%) and MQC (22.4%).
However, HQC only showed a difference of 5.4% from initial
concentration.
3.2.7. % recovery and matrix effect
Percentage recovery of RIF was measured by dividing the AUC
values of extracted QC samples with direct injection of solu-
tion containing the same nominal concentration of compounds
as the QC samples in extracted blank plasma. RIF recovery from
plasma spiked with 75, 600, and 4800 ng/mL of RIF was 92.5 ± 2.17,
93.2 ± 3.04 and 94.0 ± 2.70, respectively (n = 6). IS recovery at
250 ng/mL of RPT was 96.93 ± 2.39.
Post-column infusion experiments conﬁrmed the absence of
regions with severe matrix effects (i.e. no sharp drops or increases
in the response) for heat-treated and untreated blank human
plasma extracted with the developed method (Fig. 3). Moreover,
no suppression/enhancement for RIF could be detected when com-
pound in neat injection solvent was compared with compound in
extracted blank biological matrix.
3.2.8. Analysis of clinical samples
This method has been used for the measurement of RIF
concentration in patient plasma and CSF samples (Table 5).
Plasma-concentration data was analyzed by non-compartmental
analysis using the Kinetica software package (Thermo Electron
Corporation, UK) to obtain pharmacokinetic parameters (Table 4)
including area under the curve (AUC0–t) with extrapolation to
A. Srivastava et al. / Journal of Pharmaceutical and Biomedical Analysis 70 (2012) 523– 528 527
Table 2
Intra- and inter-day precision and accuracy data for assays of RIF in human plasma.
Inter-day (n = 18) Intra-day (n = 6)
Mean conc.a (ng/mL) CV % Accuracy % Mean conc. (ng/mL) CV % Accuracy %
LLOQ (25 ng/mL) 23.23 ± 1.34 5.78 92.93 24.64 ± 1.51 6.16 98.58
LQC  (75 ng/mL) 79.07 ± 6.13 7.75 105.43 82.59 ± 1.52 1.85 110.12
MQC  (600 ng/mL) 641.33 ±  37.74 5.88 106.89 649.10 ±  16.81 2.59 108.18
HQC  (4800 ng/mL) 5156.19 ±  268.85 5.21 107.42 4846.14 ± 109.91 2.27 100.96











Table 3HLOQ  (6400 ng/mL) 6610.76 ± 223.44 3.38 
a The inter- and intra-assay data represent the mean ± S.D. of 18 and 6 observatio
nﬁnity (AUC ) and apparent elimination half-life (t ) values.0–∞ 1/2
aximum plasma concentration (Cmax), the time-to-maximum
oncentration (Tmax) values were obtained by visual inspection of
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ig. 3. MRM  chromatograms obtained after injection of extracted (A) heat-treated
nd  (B) untreated blank human plasma during post column infusion of RIF (I) and RPT
II). A mixture containing 250 ng/mL RIF and RPT in methanol was  infused directly
y  syringe pump through a T-connector in to the MS at a constant ﬂow rate of
0  l/min, whilst the blank plasma extract was injected via the autosampler.
Stability of RIF in extracted sample and human plasma.a
Treatment LQC MQC HQC
Extracted sample/autosampler 4.0 −2.5 −0.8
Plasma/heat- inactivation 20.9 22.4 5.4
Plasma/3 × freeze–thaw −5.3 2.0 4.6
a Data represented as % difference from initial sample.
Table 4






AUC0–t (ng h/mL) 27822.9
AUC0–∞ (ng h/mL) 27948.8
a Data presented here is from one patient only.
Table 5
Quantiﬁcation of RIF in human CSF after an oral dose of 10 mg/kg/day.
Sample ID RIF concentration (ng/mL)
Patient 1 day 0 BLQa
Patient 1 day 3 28.78
Patient 1 day 6 39.49
Patient 1 day 27 30.62
Patient 1 day 62 41.83
Patient 1 day 83 25.59
Patient 2 day 0 BLQ
Patient  2 day 55 96.89
Patient 2 day 83 268.84a BLQ, below limit of quantiﬁcation.
4. Conclusion
An LC/ESI–MS/MS method was  developed and validated for the
determination of RIF in human plasma. The sample pre-treatment
was a single-step liquid–liquid extraction procedure without any
requirement for a drying step for sample concentration. Usually
drying and reconstitution step is used to obtain lower sensitiv-
ity but the present method directly gives sensitivity as low as
25 ng/mL, further we can still go lower by adding drying and recon-
stitution step to the current method. This assay requires only a
small volume of plasma (100 l). This may  be of particular advan-
tage for pediatric studies where children can only provide small
volumes of blood, and when studying RIF concentrations in the CSF
where sample volumes are limited. MTB  is generally not present
in large amounts in human plasma; however, the potential of HIV
and/or hepatitis co-infection means that plasma samples need to
be heat inactivated (58 ◦C, 40 min), however, data shown here indi-
cate that the process of heat-inactivation signiﬁcantly affects the
size of the RIF signal. Therefore, we recommend the omission of




























[28 A.  Srivastava et al. / Journal of Pharmaceut
In conclusion, method validation following FDA guideline indi-
ated that the developed method had high sensitivity with an LLOQ
f 25 ng/mL, high recovery (>90%), reliability, speciﬁcity and excel-
ent efﬁciency with a total running time of 6.0 min  per sample,
hich is important for large batches of samples. The sensitive,
imple and rapid LC/MS/MS assay is suitable for pharmacokinetic,
ioavailability or bioequivalence studies of RIF in human subjects.
his method has been successfully applied to analyze RIF concen-
rations in human plasma and CSF.
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